Gedatolisib, Faslodex, and Ibrance combination significantly improved progression-free survival in advanced breast cancer patients, reducing disease progression risk by 76%. The triplet regimen ...
Results from the OPEB-01/APGOT-OV4 trial highlight the potential benefits of using olaparib, pembrolizumab, and bevacizumab as a triplet maintenance therapy for patients who have responded to ...
ORLANDO, Florida — A new triplet therapy, comprising carfilzomib (Kyprolis, Amgen), dexamethasone, and daratumumab (Darzalex, Amgen), known as KdD, should become a new standard of care in the ...
With doublet therapy the established frontline standard of care for advanced clear cell renal carcinoma (ccRCC), researchers are investigating the possibilities of triplet regimens and other novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback